• 下载App


  • 在线客服

成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Concludes its Annual Audit with MaloneBailey, LLP
CB Science,Inc.与MaloneBailey,LLP共同完成年度审计

Accesswire ·  {{timeTz}}

Achieving Major Milestone Squarely Positions the Company for Uplisting to the OTCQB® Venture Market


ESCONDIDO, CA / ACCESSWIRE / March 15, 2022 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that MaloneBailey, LLP has successfully concluded its annual audit of the Company in accordance with Public Company Accounting Oversight Board standards, and consequently issued their favorable Auditor's Report on March 14, 2022.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2022年3月15日/CB Science。公司(场外交易代码:CBSC)(以下简称“CBSC”或“公司”)今天宣布,MaloneBailey,LLP已根据上市公司会计监督委员会的标准成功完成了对公司的年度审计,并于2022年3月14日发布了对其有利的审计师报告。

"We are extremely satisfied to have achieved this critical milestone in the Company's concentrated effort to better position CBSC in the pursuit of our planned business objectives, including an uplist to the OTCQB® Venture Market (OTCQB)," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "Completing a PCAOB audit is one of many stringent requirements stipulated by the OTC MARKETS OTCQB application process, so having already addressed other stated conditions, we anticipate final approval to be forthcoming."

CB Science,Inc.首席执行官查尔斯·马丁说:“我们非常满意在公司集中努力使CBSC更好地定位于我们计划的业务目标(包括提升到OTCQB®风险市场(OTCQB))的过程中实现了这一关键里程碑,”CB Science,Inc.的首席执行官查尔斯·马丁(Charles Martin)说。完成PCAOB审计是场外市场OTCQB申请程序规定的许多严格要求之一,因此,在解决了其他规定的条件后,我们预计将获得最终批准。

The Company believes that an uplist to the OTCQB will provide enhanced investor benefits, including more comprehensive compliance requirements, higher reporting standards, and greater access to analyst coverage.


"This significant accomplishment allows the Company to move forward with several previously announced corporate initiatives pursuant to the results of our recent Special Stockholder Meeting," said Paul Danner, Chairman of CB Scientific, Inc. "Based on the clear shareholder mandate delivered at the meeting in January, we are ready to move forward with our plans to implement a corporate name change which more accurately describes our business direction and future growth potential, relocate our corporate domicile to Nevada which provides superior tax laws and corporate regulations, increasing the number of our authorized common shares to facilitate essential fundraising aspirations, as well as certain other actions necessary to properly position us for a potential listing on the Nasdaq Capital Markets exchange at the appropriate point in the future."

CB Science,Inc.董事长保罗·丹纳说:“这一重大成就使公司能够根据我们最近召开的特别股东会议的结果,推进之前宣布的几项公司计划。基于1月份会议上提出的明确的股东授权,我们准备推进我们的计划,实施更准确地描述我们业务方向和未来增长潜力的公司名称,将我们的公司注册地迁至内华达州,那里提供了优越的税法和公司法规,增加我们授权的普通股数量,以促进必要的筹资愿望,以及某些其他必要的行动,以使我们为未来可能在纳斯达克资本市场交易所上市做好准备。“

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,使其股东、行业参与者和公开市场随时了解情况。

About CB Scientific, Inc.

关于CB Science,Inc.

CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

CB Science,Inc.通过其国内和国际子公司,在动态非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件和适用于iOS和Android平台的智能手机应用程序为有异常心律风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:


Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电子邮件:General Query:Info@cbScience ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.


SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.

View source version on accesswire.com: